Intellia Therapeutics, Inc. (NTLA): Price and Financial Metrics
NTLA Price/Volume Stats
Current price | $9.64 | 52-week high | $34.87 |
Prev. close | $9.51 | 52-week low | $8.96 |
Day low | $9.33 | Volume | 2,068,500 |
Day high | $9.72 | Avg. volume | 2,913,921 |
50-day MA | $11.60 | Dividend yield | N/A |
200-day MA | $19.05 | Market Cap | 981.82M |
NTLA Stock Price Chart Interactive Chart >
Intellia Therapeutics, Inc. (NTLA) Company Bio
Intellia Therapeutics a gene editing company, develops therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
NTLA Price Returns
1-mo | -0.72% |
3-mo | -30.99% |
6-mo | -57.40% |
1-year | -66.14% |
3-year | -90.22% |
5-year | -30.45% |
YTD | -17.32% |
2024 | -61.76% |
2023 | -12.61% |
2022 | -70.49% |
2021 | 117.35% |
2020 | 270.82% |
Continue Researching NTLA
Want to see what other sources are saying about Intellia Therapeutics Inc's financials and stock price? Try the links below:Intellia Therapeutics Inc (NTLA) Stock Price | Nasdaq
Intellia Therapeutics Inc (NTLA) Stock Quote, History and News - Yahoo Finance
Intellia Therapeutics Inc (NTLA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...